Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Biocatalyst product sales	$ 2,020	$ 2,776	$ 5,097	$ 5,761
Biocatalyst research and development	2,533	1,666	4,729	3,812
Revenue sharing arrangement	1,465	2,128	2,990	4,071
Total revenues	6,018	6,570	12,816	13,644
Costs and operating expenses:
Cost of biocatalyst product sales	1,250	2,123	2,706	4,647
Research and development	5,170	7,733	10,463	12,567
Selling, general and administrative	5,296	5,625	10,874	11,737
Total costs and operating expenses	11,716	15,481	24,043	28,951
Loss from operations	(5,698)	(8,911)	(11,227)	(15,307)
Interest income	4	3	8	12
Other expenses	(96)	(8)	(121)	(126)
Loss before income taxes	(5,790)	(8,916)	(11,340)	(15,421)
Benefit from income taxes	(430)	(437)	(418)	(567)
Net loss	$ (5,360)	$ (8,479)	$ (10,922)	$ (14,854)
Net loss per share, basic and diluted (dollars per share)	$ (0.14)	$ (0.22)	$ (0.28)	$ (0.39)
Weighted average common shares used in computing net loss per share, basic and diluted (shares)	39,301	37,980	39,066	37,862